Equivalence pharmaceutical equivalents---drugs must have same active ingredients, in same strength, in same dosage form, same RofA. Inactive ingredients.

Slides:



Advertisements
Similar presentations
Equivalence Tests in Clinical Trials
Advertisements

Drug design and testing,. Drug Names Chemical name- describes its molecular structure and distinguishes it from other drugs.
Bioequivalence Studies Anoop Agarwal
Recent Advances in BCS and Drug Product (BioPredictive) Dissolution
III. Drug Metabolism  The aim of drug metabolism is to convert lipid soluble (non polar) drugs to polar metabolites easily excreted in urine.  The liver.
Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.
Skin Stripping vs. Acne Bioequivalent Studies for Tretinoin Generics. Comments at FDA-Advisory Meeting Nov 17, 2000 K.L. Spear M.D. / Dermatologist Spear.
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence.
What is a Generic Medication?. The World Health Organization Definition of a Generic Medication A generic drug is a pharmaceutical product, usually intended.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
Bioavailability and Bioequivalence
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Hanoi, WORKSHOP ON PREQUALIFICATION OF ARV: BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence Study Design and Conduct Presented.
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.
AND GENERIC DRUGS BRAND-NAME AND GENERIC DRUGS WHAT TO CHOOSE? Natalia VEZIKOVA, MD, PhD, Natalia VEZIKOVA, MD, PhD, MSc The Head of the Hospital Therapy.
WHO Prequalification Program Workshop, Kiev, Ukraine, June 25-27,2007.
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Bioequivalence of Topical Drug Products
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Bioequivalence Studies Dr Sanet Aspinall, PhD Managing Director AddClin Research Pretoria 20 March 2009.
What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.
Prequalification project Drs. Jan Welink. * Note to applicants on the choice of comparator products for the prequalification.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
ERT 420 BIOPHARMACEUTICAL ENGINEERING ERT 420 BIOPHARMACEUTICAL ENGINEERING Semester 1 Academic Session 2012/2013 HUZAIRY HASSAN School Of Bioprocess Engineering.
Generic Substitution of AEDs: Is There Cause for Concern? Barry E. Gidal, PharmD Professor of Pharmacy and Neurology University of Wisconsin School of.
Biomedical Research Objective 2 Biomedical Research Methods.
Week 6- Bioavailability and Bioequivalence
FDA Focus On Consumer Protection
ACPS Meeting, October 19-20, 2004 BioINequivalence: Concept and Definition Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs, OPS, CDER,
Slide 1 Review of the Drug Formulary Commission Bureau of Health Care Safety and Quality Department of Public Health September 8, 2015.
SYSTEMIC ABSORPTION AS THE MOST ACCURATE AND SENSITIVE METHOD OF DETERMINING BIOEQUIVALENCE OF GENERIC TOPICAL PRODUCTS Chris Hendy Ph.D. Novum Pharmaceutical.
AXINN, VELTROP & HARKRIDER LLP © 2007 | AXINN, VELTROP & HARKRIDER LLP Click To Modify Title Name Goes Here Bioequivalence - What Patent.
Center for Professional Advancement Generic Drug Approvals Course Bioequivalence & Bioavailability Michael A. Swit, Esq. Vice President.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
1 Abu Alam Ph.D. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 23, 2008.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Bioequivalence Dr Mohammad Issa Saleh.
Miracle Drugs. THE FDA Food and Drug Administration They determine if…….. –Safe (it wont hurt you) –Effective (it will do what it says)
Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
BASIC BIOPHARMACEUTICS
Using Product Development Information to Address the Bioequivalence Challenges of Highly-variable Drugs Lawrence X. Yu, Ph. D. Director for Science Office.
Introduction What is a Biowaiver?
Bioavailability and Bioequivalence General concepts and overview
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Bioavailability and Bioequivalence L 10,11.  Bioavailability is a measurement of the rate and extent (amount) to which the active ingredient or active.
Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
Topic #2: Quality by Design and Pharmaceutical Equivalence Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Science Center for Drug Evaluation and Research.
 An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate.
OVER THE COUNTER MEDS INTRODUCTION No prescriptions are necessary and no questions need to be answered to attain these drugs OTC med use saves.
Regulation of Generic Animal Drugs in the United States
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Definitions and Concepts
- Pharmaceutical Equivalence Study
BASICS IN PHARMA.
Introduction What is a Biowaiver?
Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.
CHAWLA MEDICOS Present’s Branded v/s Generic medicine
Package Inserts As mention before, the drug package insert is part of the labeling of the drug product It is required by the FDCA of 1938 See lesson 3.
Drug design and testing,
Pharmacokinetics & pharmacodynamcs
Clinical Pharmacokinetics
Drug and Drug Products Quality & Testing
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
Objective 2 Biomedical Research Methods
Presentation transcript:

equivalence pharmaceutical equivalents---drugs must have same active ingredients, in same strength, in same dosage form, same RofA. Inactive ingredients can vary. pharmaceutical alternatives---they have same moiety(chemistry) but different salts,esters. tetracycline HCl vs tetracycline phosphate bioavailability----measures rate and extent to which active ingredient is absorbed from a dosage form and becomes available at site of action.

equivalence bioequivalent drug products---describes pharm equiv or pharm alternative products that have comparable bioavailability when studies done under similar experimental conditions. not much difference in rate and extent of absorption. therapeutic equivalents---drugs must be pharmaceutical equ and bioequivalent. FDA says drugs are equivalent if 1--safe and effective 2--pharm equ of same amount active ingredient and standard of purity/quality 3—bioequivalent 4--- adequately labeled 5---in compliance with current good manufacturing practice regulations.

bioequivalence study used to determine if a second drug is bioequivalent to a standard drug. study includes healthy adults. standard drug is measured in the person then second drug is done. bioequivalence of results are 20%less to 25%over standard drug bioavailability % range is clinically insignificant.

therapeutic equivalence ratings FDA determines the standard drug. this is called ‘orange book’ you can use the book to determine if a product has been tested or approved as their equivalent. rating A = equiv approved B=not equiv or no comparison found what are some B rating drugs?--warfarin, digoxin, synthroid..because dosage is very delicate to work. DESI---Drug Efficacy Study Implementation. older drugs( ) were tested in 1973 and most found ‘ineffective’. Insurance companies usually deny DESI drugs.